This article describes the development and testing of a genetically engineered bacterium, SYNB1891, for the treatment of cancer. The bacterium is designed to produce cyclic-di-AMP (CDA), a stimulator of the STING pathway, which activates the immune system to fight cancer. The researchers tested SYNB1891 in various mouse models of cancer, including melanoma, lymphoma, and colon cancer, and found that it was able to inhibit tumor growth and induce immune responses. They also tested the safety and efficacy of SYNB1891 in vitro and in vivo, and found that it was well-tolerated and able to induce cytokine production and immune cell activation. The researchers used various techniques, including flow cytometry, qPCR, and ELISA, to analyze the immune responses induced by SYNB1891. They also developed a method for quantifying CDA production in vitro and in vivo using LC-MS/MS. Overall, the study suggests that SYNB1891 is a promising candidate for cancer immunotherapy, and provides a foundation for further research and development.
Engineered bacteria-based immunotherapy targets the STING pathway to enhance anti-tumor immune response.
